CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 15 enrolled
Drug / intervention
NOV-002 +1 moredrug
Likely dose
NOV-002 60 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00345540
NCT00345540Phase 2Completed
CompareCT.gov

Phase 2 Trial of NOV-002 With Carboplatin in Women With Recurrent and Platinum Resistant Tumors of Mullerian Origin

Cellectar Biosciences, Inc.·interventional·Posted Jun 28, 2006·Updated Mar 10, 2015

In Brief

A Phase 2 clinical trial evaluating NOV-002 and Carboplatin for Ovarian Cancer. Completed, enrolled 15 participants across 2 sites.

Detailed Summary

The purpose of this trial is to determine the tumor response rate of NOV-002 plus carboplatin in a cohort of women with platinum resistant cancer of ovarian origin.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOvarian Cancer
CountriesUnited States
CollaboratorsMassachusetts General Hospital, Dana-Farber Cancer Institute

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 28, 2006
Enrollment StartJul 1, 2006
Primary CompletionMay 1, 2008
Study CompletionJun 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 20.0 years ago

Interventions

NOV-002drug

60 mg / mL / day / 20-23 Days

Carboplatindrug

AUC 5 following IV bolus administration of NOV-002